ClinicalTrials.gg
RecruitingNCT07849608Updated Sep 30, 2026

Silent Evaluation of DeepTRG for Assessing Tumor Response After Preoperative Treatment in Stomach and Gastroesophageal Junction Cancer

An observational study in Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma, sponsored by Qun Zhao. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Qun Zhao · Observational

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Sep 30, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
18 Years and older
Sex
All
01

Study summary

This study will evaluate whether an artificial intelligence (AI) system called DeepTRG can reliably assess cancer tissue removed during surgery after treatment given before surgery. It will include adults with stomach cancer or cancer at the junction between the stomach and the food pipe who have received treatment before surgery.

Pathologists are doctors who examine tissue to diagnose disease. After cancer surgery, they assess how much living cancer remains and whether cancer is present in nearby lymph nodes. DeepTRG analyzes digital images of tissue slides to measure remaining cancer and describe tissue changes, such as scarring and inflammation. It combines information from the original tumor site and lymph nodes to produce a structured assessment.

The main question is:

* How often can DeepTRG complete the required assessment and produce a clear result without a person correcting the AI analysis?

The study will also examine:

  • How closely the system's measurements agree with assessments made by independent expert pathologists.
  • How accurately it detects remaining cancer, including small amounts of cancer and cancer in lymph nodes.
  • How long the analysis takes and how often it fails or produces an uncertain result.
  • Whether its performance differs across treatment types and cancer tissue types.

This study will take place at the Fourth Hospital of Hebei Medical University in China. Eligible patients will be enrolled consecutively. Researchers will use tissue collected during the patients' planned surgery. No additional surgery or biopsy is required for this study.

DeepTRG will run in the background in "silent mode." The doctors responsible for the patients' routine pathology reports and treatment decisions will not receive its results. Patients will continue to receive usual care. The AI model and its grading rules will be fixed before validation begins.

Independent expert pathologists will assess the tissue without seeing the AI results. Researchers will then compare the expert assessments, routine pathology reports, and DeepTRG outputs. Cases with poor-quality images, failed analyses, or uncertain outputs will remain part of the assessment of how reliably the system works.

Researchers will also collect information about subsequent treatment, cancer recurrence, and survival during follow-up. The initial analysis will focus on feasibility and measurement performance. A separate future study would be needed to determine whether using DeepTRG in clinical care improves doctors' decisions or patient outcomes.

02

Conditions studied

  • Gastric Adenocarcinoma
  • Gastroesophageal Junction Adenocarcinoma
03

In context

Lead sponsor

Qun Zhao is the lead sponsor of 16 studies on the registry; 10 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Probability sample

Study population

Consecutive adults with histologically confirmed gastric or Siewert type II or III gastroesophageal junction adenocarcinoma who have received neoadjuvant treatment and are scheduled for surgical resection with curative intent at the Fourth Hospital of Hebei Medical University, China. Eligible patients will be approached consecutively during the recruitment period, before postoperative pathological response is known. Routinely collected primary tumor and regional lymph node specimens will be evaluated. DeepTRG will operate in silent mode, with its outputs withheld from routine reporting pathologists and treating clinicians. Technical failures and unassessable cases will be retained in the feasibility analysis.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older.
  • confirmed adenocarcinoma of the stomach or gastroesophageal junction (Siewert type II or III), diagnosed before treatment.
  • Received neoadjuvant anticancer treatment before planned surgical resection.
  • Scheduled to undergo surgical resection with curative intent at the Fourth Hospital of Hebei Medical University, with routine pathological examination of the primary tumor site and regional lymph nodes.
  • Written obtained in accordance with the ethics-approved study protocol.

Exclusion criteria

Exclusion Criteria:

  • Non-adenocarcinoma , including squamous cell carcinoma, lymphoma, gastrointestinal stromal tumor, or neuroendocrine carcinoma.
  • Surgery for recurrent gastric or gastroesophageal junction cancer.
  • Previous inclusion of the patient's tissue or data in DeepTRG model training, grading-rule development, or parameter tuning.

Patients will not be excluded because of a complete pathological response, positive surgical margins, poor-quality or unavailable slides, digitization failure, algorithm failure, or uncertain or unassessable DeepTRG results. Technical limitations identified after enrollment will be recorded and retained in the feasibility analysis. Patients who do not proceed to surgical resection will be documented in the study flow and will not contribute to the specimen-based primary outcome denominator.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Target follow-up
2 Years
Patient registry
Yes

Interventions

  • Diagnostic testAI-Based Digital Pathology Assessment of Treatment Response (DeepTRG)

    DeepTRG is an AI-based digital pathology system applied to whole-slide images of routinely collected hematoxylin and eosin-stained tissue from the primary tumor site and regional lymph nodes after neoadjuvant therapy and surgical resection. It quantifies residual viable tumor and treatment-related tissue changes and generates a patient-level pathological response grade with quality and uncertainty indicators. The model and grading rules will be locked before prospective validation. The system will operate in silent mode: outputs will be stored for research and withheld from treating clinicians and routine reporting pathologists. Results will be compared with routine pathology reports and independent expert assessments. Processing time, analysis failures, and uncertain outputs will be recorded. No additional biopsy or change in treatment will be required.

06

What researchers measure

Primary outcomes

  1. Patient-Level Complete Automated Assessment Rate

    Percentage of enrolled patients undergoing surgical resection for whom DeepTRG generates a complete patient-level pathological response assessment within the specified assessment window, without manual correction of AI-generated segmentations, measurements, or grades. A successful assessment must include the final DeepTRG grade and all required primary tumor and regional lymph node outputs, meet prespecified quality criteria, and have no unresolved uncertainty requiring manual adjudication. The AI model, grading rules, required outputs, and quality criteria will be locked before enrollment. The denominator will include all enrolled patients undergoing eligible surgical resection, including those with unavailable or inadequate slides, digitization failures, processing failures, or unassessable or uncertain outputs. These cases will be counted as unsuccessful assessments. The rate will be reported with a 95% confidence interval.

    Time frame: Within 14 days after receipt of the surgical specimen by the pathology department.

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2026 (actual). Primary completion is estimated for Dec 2026, 3 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2026
First posted
Sep 30, 2026
StartActual
Sep 1, 2026
Primary completionEst.
Dec 30, 2026
CompletionEst.
Dec 30, 2026
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07849608
Lead sponsor
Qun Zhao
Responsible party
Qun Zhao (Professor, Hebei Medical University) — Sponsor-investigator
First posted
Sep 30, 2026
Start date
Sep 1, 2026
Primary completion
Dec 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Sep 30, 2026

Study contacts

Ping'an Ding
Contact
ding_ping_an@hebmu.edu.cn
031186095363

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion